| Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and … JD Stanaway, A Afshin, E Gakidou, SS Lim, D Abate, KH Abate, ... The Lancet 392 (10159), 1923-1994, 2018 | 7067* | 2018 |
| Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to … C Fitzmaurice, C Allen, RM Barber, L Barregard, ZA Bhutta, H Brenner, ... JAMA oncology 3 (4), 524-548, 2017 | 7023 | 2017 |
| Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 T Vos, SS Lim, C Abbafati, KM Abbas, M Abbasi, M Abbasifard, ... The lancet 396 (10258), 1204-1222, 2020 | 7012 | 2020 |
| Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study GA Roth, GA Mensah, CO Johnson, G Addolorato, E Ammirati, ... Journal of the American college of cardiology 76 (25), 2982-3021, 2020 | 5931 | 2020 |
| Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the … T Vos, AA Abajobir, KH Abate, C Abbafati, KM Abbas, F Abd-Allah, ... The Lancet 390 (10100), 1211-1259, 2017 | 5452 | 2017 |
| Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 B Bikbov, CA Purcell, AS Levey, M Smith, A Abdoli, M Abebe, ... The lancet 395 (10225), 709-733, 2020 | 4322 | 2020 |
| Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 … HH Kyu, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ... The Lancet 392 (10159), 1859-1922, 2018 | 3838 | 2018 |
| Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 C Abbafati, DB Machado, B Cislaghi, OM Salman, M Karanikolos, ... Deakin University, 2020 | 979 | 2020 |
| Five insights from the global burden of disease study 2019 CJL Murray, C Abbafati, KM Abbas, M Abbasi, M Abbasi-Kangevari, ... The Lancet 396 (10258), 1135-1159, 2020 | 576 | 2020 |
| Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic … MB Reitsma, PJ Kendrick, E Ababneh, C Abbafati, M Abbasi-Kangevari, ... The Lancet 397 (10292), 2337-2360, 2021 | 444 | 2021 |
| Diabetes in Iran: prospective analysis from first nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016) A Esteghamati, B Larijani, MH Aghajani, F Ghaemi, J Kermanchi, ... Scientific reports 7 (1), 13461, 2017 | 341 | 2017 |
| Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries … AY Chang, K Cowling, AE Micah, A Chapin, CS Chen, G Ikilezi, N Sadat, ... The Lancet 393 (10187), 2233-2260, 2019 | 335 | 2019 |
| Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020 D Bryazka, MB Reitsma, MG Griswold, KH Abate, C Abbafati, ... The Lancet 400 (10347), 185-235, 2022 | 221 | 2022 |
| Mapping child growth failure across low-and middle-income countries Nature 577 (7789), 231-234, 2020 | 171 | 2020 |
| Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial A Ghajar, SM Neishabouri, N Velayati, L Jahangard, N Matinnia, ... Pharmacopsychiatry 50 (04), 152-160, 2017 | 118 | 2017 |
| Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial M Jafarinia, M Afarideh, A Tafakhori, M Arbabi, A Ghajar, AA Noorbala, ... Journal of affective disorders 204, 1-8, 2016 | 101 | 2016 |
| Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency H Abolhassani, J Chou, W Bainter, CD Platt, M Tavassoli, T Momen, ... Journal of Allergy and Clinical Immunology 141 (4), 1450-1458, 2018 | 97 | 2018 |
| Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial S Arabzadeh, E Hakkikazazi, N Shahmansouri, A Tafakhori, A Ghajar, ... Journal of affective disorders 235, 236-241, 2018 | 65 | 2018 |
| Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial M Ghazizadeh-Hashemi, A Ghajar, MR Shalbafan, ... Journal of affective disorders 232, 127-133, 2018 | 63 | 2018 |
| Prevalence of metabolic syndrome in Iran: A 2011 update: 伊朗的代谢综合征患病率: 2011 年更新数据 S Noshad, M Abbasi, K Etemad, A Meysamie, M Afarideh, E Khajeh, ... Journal of diabetes 9 (5), 518-525, 2017 | 49 | 2017 |
Mohsen Afarideh, MD MPHDepartment of Dermatology, Mayo ClinicVerified email at mayo.edu
